Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1951 2
1952 4
1953 3
1955 2
1960 1
1963 1
1993 2
1994 5
1995 7
1996 8
1997 44
1998 32
1999 53
2000 86
2001 98
2002 120
2003 127
2004 178
2005 163
2006 181
2007 185
2008 210
2009 200
2010 213
2011 214
2012 211
2013 220
2014 214
2015 276
2016 274
2017 301
2018 325
2019 389
2020 503
2021 547
2022 535
2023 502
2024 503
2025 459
2026 155

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,725 results

Results by year

Filters applied: . Clear all
Page 1
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF.
Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Docherty KF, et al. JACC Heart Fail. 2020 Oct;8(10):800-810. doi: 10.1016/j.jchf.2020.06.020. JACC Heart Fail. 2020. PMID: 33004114 Free PMC article. Review.
This paper reviews the current understanding of the effects of sacubitril/valsartan and highlights expected developments over the next 5 years, including potential new indications for use. Additionally, a practical, evidence-based approach is provided to the clinical integ …
This paper reviews the current understanding of the effects of sacubitril/valsartan and highlights expected developments over the nex …
Valsartan/hydrochlorothiazide.
Langtry HD, McClellan KJ. Langtry HD, et al. Drugs. 1999 May;57(5):751-5; discussion 756-8. doi: 10.2165/00003495-199957050-00008. Drugs. 1999. PMID: 10353300 Review.
In clinical trials in patients with essential hypertension, adding HCTZ 12.5 or 25 mg/day to valsartan 80 mg/day resulted in a greater blood pressure reduction than increasing the valsartan dosage from 80 to 160 mg/day. ...Valsartan/HCTZ was well tolerated in …
In clinical trials in patients with essential hypertension, adding HCTZ 12.5 or 25 mg/day to valsartan 80 mg/day resulted in a greate …
Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open-Label, Noninferiority Study (PARASOL Study).
Yamamoto K, Yarimizu D, Shimanishi A, Eguchi S, Iekushi K, Takami Y, Nozato Y, Kario K, Rakugi H. Yamamoto K, et al. J Clin Hypertens (Greenwich). 2025 Jan;27(1):e14938. doi: 10.1111/jch.14938. Epub 2024 Dec 4. J Clin Hypertens (Greenwich). 2025. PMID: 39632589 Free PMC article. Clinical Trial.
However, there has been no available evidence on the comparison between sacubitril/valsartan and calcium channel blockers (CCBs), a well-established class of antihypertensive drugs. ...Sacubitril/valsartan, a potent antihypertensive drug comparable to amlodipine, is …
However, there has been no available evidence on the comparison between sacubitril/valsartan and calcium channel blockers (CCBs), a w …
The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis.
Zhou W, Yang X, Jin J, Cheng M, Li Y, Bai Y, Xu J. Zhou W, et al. Int Urol Nephrol. 2024 Jan;56(1):181-190. doi: 10.1007/s11255-023-03599-w. Epub 2023 May 17. Int Urol Nephrol. 2024. PMID: 37195574
To assess the efficacy and safety of sacubitril/valsartan for patients with CKD, we performed this meta-analysis. METHODS: The Embase, PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) that compared sacubitril/valsartan with ACEI/ …
To assess the efficacy and safety of sacubitril/valsartan for patients with CKD, we performed this meta-analysis. METHODS: The Embase …
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Rakugi H, et al. Hypertens Res. 2022 May;45(5):824-833. doi: 10.1038/s41440-021-00819-7. Epub 2022 Jan 21. Hypertens Res. 2022. PMID: 35058583 Free PMC article. Clinical Trial.

Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitril/valsartan vs. olmesartan (P < 0.05 for all), were also observed. Patients treated with sacubitril/valsartan achieved an

…
Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitr …
Valsartan.
Ardiana F, Suciati, Indrayanto G. Ardiana F, et al. Profiles Drug Subst Excip Relat Methodol. 2015;40:431-93. doi: 10.1016/bs.podrm.2015.01.004. Epub 2015 Mar 21. Profiles Drug Subst Excip Relat Methodol. 2015. PMID: 26051690 Review.
Valsartan is an antihypertensive drug which selectively inhibits angiotensin receptor type II. Generally, valsartan is available as film-coated tablets. This review summarizes thermal analysis, spectroscopy characteristics (UV, IR, MS, and NMR), polymorphism forms, …
Valsartan is an antihypertensive drug which selectively inhibits angiotensin receptor type II. Generally, valsartan is availab …
[Valsartan contamination].
Jilesen DPMW, Kramers C, Kerkvliet CTM, Bosch FH. Jilesen DPMW, et al. Ned Tijdschr Geneeskd. 2019 Mar 28;163:D3699. Ned Tijdschr Geneeskd. 2019. PMID: 30945826 Dutch.
The valsartan contamination raises the question of whether or not the Dutch authorities involved responded adequately. It has become clear from the contamination of valsartan that good and timely communication is important....
The valsartan contamination raises the question of whether or not the Dutch authorities involved responded adequately. It has become …
Sacubitril/Valsartan-induced Angioedema.
Hiraoka Y, Nagayama K. Hiraoka Y, et al. Intern Med. 2024;63(18):2583. doi: 10.2169/internalmedicine.3183-23. Epub 2024 Sep 15. Intern Med. 2024. PMID: 39284739 Free PMC article. No abstract available.
Association between treatment with sacubitril/valsartan and the risk of Alzheimer's disease: a clinical update.
Garnier-Crussard A. Garnier-Crussard A. Alzheimers Res Ther. 2024 Aug 1;16(1):177. doi: 10.1186/s13195-024-01547-z. Alzheimers Res Ther. 2024. PMID: 39090680 Free PMC article. Review.
Since 2014, sacubitril/valsartan (Entresto( )) is widely prescribed for heart failure. Despite neprilysin inhibition's benefits in heart failure, concerns about potential amyloid-beta (Abeta) accumulation and Alzheimer's disease (AD) risk have persisted. ...In patients tre …
Since 2014, sacubitril/valsartan (Entresto( )) is widely prescribed for heart failure. Despite neprilysin inhibition's benefits in he …
Effects of sacubitril-valsartan on aging-related cardiac dysfunction.
Telesca M, De Angelis A, Donniacuo M, Bellocchio G, Riemma MA, Mele E, Canonico F, Cianflone E, Torella D, D'Amario D, Patti G, Liantonio A, Imbrici P, De Luca A, Castaldo G, Rossi F, Cappetta D, Urbanek K, Berrino L. Telesca M, et al. Eur J Pharmacol. 2024 Sep 5;978:176794. doi: 10.1016/j.ejphar.2024.176794. Epub 2024 Jul 3. Eur J Pharmacol. 2024. PMID: 38968980 Free article.
No differential action of sacubitril/valsartan versus valsartan alone, either positive or negative, was observed. The positive effects of both sacubitril/valsartan and valsartan on cardiac hypertrophy was evidenced by a significant reduction of wall th …
No differential action of sacubitril/valsartan versus valsartan alone, either positive or negative, was observed. The positive …
6,725 results